Trade Incyte Corporation - INCY CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.16 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.026235% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004012% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 62.9 |
| Open | 62.8 |
| 1-Year Change | -2.38% |
| Day's Range | 61.57 - 62.8 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 11, 2024 | 62.90 | 0.33 | 0.53% | 62.57 | 63.09 | 61.53 |
| Sep 10, 2024 | 63.05 | 1.20 | 1.94% | 61.85 | 63.26 | 61.36 |
| Sep 9, 2024 | 62.19 | 0.92 | 1.50% | 61.27 | 62.74 | 61.02 |
| Sep 6, 2024 | 61.19 | -1.45 | -2.31% | 62.64 | 63.50 | 60.90 |
| Sep 5, 2024 | 62.90 | -1.30 | -2.02% | 64.20 | 64.20 | 61.02 |
| Sep 4, 2024 | 64.25 | -1.74 | -2.64% | 65.99 | 66.67 | 63.93 |
| Sep 3, 2024 | 66.24 | 1.26 | 1.94% | 64.98 | 67.01 | 64.98 |
| Aug 30, 2024 | 65.59 | -0.22 | -0.33% | 65.81 | 66.18 | 64.71 |
| Aug 29, 2024 | 65.86 | 0.59 | 0.90% | 65.27 | 67.42 | 64.96 |
| Aug 28, 2024 | 65.59 | 0.90 | 1.39% | 64.69 | 65.84 | 64.69 |
| Aug 27, 2024 | 65.58 | 0.71 | 1.09% | 64.87 | 65.63 | 64.85 |
| Aug 26, 2024 | 65.13 | 1.18 | 1.85% | 63.95 | 65.34 | 63.68 |
| Aug 23, 2024 | 64.07 | 0.67 | 1.06% | 63.40 | 64.38 | 62.99 |
| Aug 22, 2024 | 62.78 | -1.28 | -2.00% | 64.06 | 64.12 | 62.59 |
| Aug 21, 2024 | 64.08 | -0.20 | -0.31% | 64.28 | 64.81 | 63.86 |
| Aug 20, 2024 | 64.16 | 1.41 | 2.25% | 62.75 | 64.71 | 62.75 |
| Aug 19, 2024 | 63.18 | 1.13 | 1.82% | 62.05 | 63.23 | 61.80 |
| Aug 16, 2024 | 62.10 | 0.40 | 0.65% | 61.70 | 62.41 | 61.15 |
| Aug 15, 2024 | 61.61 | 0.29 | 0.47% | 61.32 | 62.09 | 61.20 |
| Aug 14, 2024 | 61.12 | -0.08 | -0.13% | 61.20 | 61.90 | 60.89 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Incyte Company profile
About Incyte Corporation
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development and commercialization of therapeutics. The Company also conducts commercial and clinical development operations from its European headquarters in Morges, Switzerland and Japanese office in Tokyo. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise is comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as other clinical development programs. Its Dermatology commercial franchise is comprised of OPZELURA (ruxolitinib) cream and other clinical development programs.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Incyte Corporation revenues increased 12% to $2.99B. Net income totaled $948.6M vs. loss of $295.7M. Revenues reflect JAKAFI revenues segment increase of 10% to $2.13B, OLUMIANT product royalty revenues segment increase of 99% to $220.9M. Net Income reflects Other Research and development decrease of 47% to $902.3M (expense), Change in fair value of acquisition-rela decrease of 37% to $14.7M (expense).
Equity composition
Common Stock $.001 Par, 04/11, 400M auth.,124,585,982. issd. Insiders & stakeholders own 1.22%. IPO: 11/93, 2M shares @ $7.50by D. Blech and Co. PO 11/95, 1.7M shares @ $19 by Hambrecht & Quist. PO 9/97, 1.38M shs @ $67 by Hambrecht & Quist. 9/00, 11/97, 2-for-1 stock splits. 6/00, Name chgd. from Incyte Pharmaceuticals, Inc. PO:10.5M shares
| Industry: | Biopharmaceuticals |
1801 Augustine Cut-Off
WILMINGTON
DELAWARE 19803
US
News
ECB Preview: cuts expected but the pace is uncertain
Markets expect the ECB to cut rates again in September, but how many more?
12:34, 11 September 2024
Market analysis: US CPI and PPI
Overview of upcoming US inflation data for August, with expectations for a year-over-year CPI drop to 2.6% and core CPI holding steady at 3.2%. Markets will also focus on U.S. PPI data, which is forecasted to show mild growth, reinforcing potential easing inflationary pressures.
07:56, 10 September 2024
Introducing Newsquawk: your new in-platform newsfeed
We are very excited to announce the launch of Newsquawk in the Capital.com platform and app. This new newsfeed is designed to help you get ahead with real-time headlines, personalised stories and in-depth reports – all available directly in the platform and app, where you need them.
14:09, 20 August 2024
Jackson Hole Preview: All eyes on Powell and Gold
The key focus this week will be on Jerome Powell and any insight he may give into the future of monetary policy.
15:24, 19 August 2024
All eyes on inflation: US and UK CPI take centre stage
Just over a month has gone by since the latest CPI data was released in the US and so much has happened since.
14:41, 13 August 2024
European stocks face resistance in their attempt to recover
European stocks struggle to recover as the tech sector faces continued downside pressure in Asia.
13:56, 9 August 2024
Global selloff continues on US economy fears
Thursday’s rise in jobless claims led to a market meltdown in the US stock market as investors became concerned that the Federal Reserve made the wrong decision by keeping rates unchanged on Wednesday.
14:40, 5 August 2024People also watch
Still looking for a broker you can trust?
Join the 640,000+ traders worldwide that chose to trade with Capital.com